Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways

References

• Patel YC, Greenwood MT, Panetta R, Demchyshyn H, Niznik H, Srikant CB. The somatostatin receptor family: A minireview. Life Sci 1995; 57: 1249–65
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157–98
   PubMed Web of Science ®Google Scholar
• Kimura N, Tomizawa S, Arai KN, Kimura N. Chronic treatment with estrogen up-regulatesexpression of sst2 messenger ribonucleic acid (mRNA) but down-regulates expression of sst5 mRNA in rat pituitaries. Endocrinology 1998; 139: 1573–80
   PubMedGoogle Scholar
• Hofland LJ, Lamberts SW. Somatostatin receptors and disease: Role of receptor subtypes. Baillieres Clin Endocrinol Metab 1996; 10: 163–76
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007; 156: 65–74
   PubMed Web of Science ®Google Scholar
• Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. Endocrinol Invest 2005; 28: 5
   PubMedGoogle Scholar
• Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: Advantages, disadvantages and new prospects. Endocrinol Invest 2005; 28: 36–42
   PubMedGoogle Scholar
• Petersenn S. Efficacy and limits of somatostatin analogs. Endocrinol Invest 2005; 28: 53–7
   PubMedGoogle Scholar
• Janson ET, Gobl A, Kälkner KM, Oberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 1996; 56: 2561–5
   PubMedGoogle Scholar
• Kumar M, Liu ZR, Thapa L, Wang DY, Tian R, Qin RY. Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype2. Pancreas 2004; 29: 141–51
   PubMedGoogle Scholar
• Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, et al. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin Cancer Res 2001; 7: 2854–61
   PubMedGoogle Scholar
• Kumar M, Liu ZR, Thapa L, Qin RY. Anti-angiogenic effects of somatostatin receptor subtype2 on human pancreatic cancer xenografts. Carcinogenesis 2004; 25: 2075–81
   PubMedGoogle Scholar
• Celinski SA, Fisher WE, Amaya F, Wu YQ, Yao Q, Youker KA, et al. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J Surg Res 2003; 115: 41–7
   PubMedGoogle Scholar
• Cattaneo AG, Taylor JE, Culler MD, Nisoli E, Vicentini LM. Selective stimulation of somatostatin receptor subtypes: Differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 2000; 481: 271–6
   PubMedGoogle Scholar
• Liu AM, Wong YH. Activation of nuclear factor {kappa}B by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves G{alpha}14 and multiple signaling components: A mechanism requiring protein kinase C, calmodulin-dependent kinase II, ERK, and c-Src. J Biol Chem 2005; 280: 34617–25
   PubMedGoogle Scholar
• Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008; 158: 295–303
   PubMed Web of Science ®Google Scholar
• Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002; 62: 6124–31
   PubMed Web of Science ®Google Scholar
• Teijeiro R, Rios R, Costoya JA, Castro R, Bello JL, Devesa J, et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 2002; 12: 31–8
   PubMed Web of Science ®Google Scholar
• Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006; 13: 955–62
   PubMed Web of Science ®Google Scholar
• Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007; 13: 5991–3
   PubMed Web of Science ®Google Scholar
• Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10: 138–47
   PubMed Web of Science ®Google Scholar
• Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Patents Anticancer Drug Discov 2007; 2: 59–71
   PubMed Web of Science ®Google Scholar
• Murate T, Hayakawa T. Multiple functions of tissue inhibitors of metalloproteinases (TIMPs): New aspects in hematopoiesis. Platelets 1999; 10: 5–16
   PubMed Web of Science ®Google Scholar
• Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003; 88: 4239–45
   PubMed Web of Science ®Google Scholar